79 related articles for article (PubMed ID: 15124132)
1. SEOM guidelines for the management of Malignant Melanoma 2015.
Berrocal A; Arance A; Espinosa E; Castaño AG; Cao MG; Larriba JL; Martín JA; Márquez I; Soria A; Algarra SM
Clin Transl Oncol; 2015 Dec; 17(12):1030-5. PubMed ID: 26669314
[TBL] [Abstract][Full Text] [Related]
2. Selective induction of cell death in melanoma cell lines through targeting of Mcl-1 and A1.
Senft D; Berking C; Graf SA; Kammerbauer C; Ruzicka T; Besch R
PLoS One; 2012; 7(1):e30821. PubMed ID: 22292048
[TBL] [Abstract][Full Text] [Related]
3. Differential expression patterns of capping protein, protein phosphatase 1, and casein kinase 1 may serve as diagnostic markers for malignant melanoma.
Sun D; Zhou M; Kowolik CM; Trisal V; Huang Q; Kernstine KH; Lian F; Shen B
Melanoma Res; 2011 Aug; 21(4):335-43. PubMed ID: 21566537
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
Zheng M; Bocangel D; Ramesh R; Ekmekcioglu S; Poindexter N; Grimm EA; Chada S
Mol Cancer Ther; 2008 Dec; 7(12):3842-51. PubMed ID: 19056673
[TBL] [Abstract][Full Text] [Related]
5. Gastrin exerts pleiotropic effects on human melanoma cell biology.
Mathieu V; Mijatovic T; van Damme M; Kiss R
Neoplasia; 2005 Oct; 7(10):930-43. PubMed ID: 16242076
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy of melanoma.
Spitler LE
Oncology (Williston Park); 2002 Jan; 16(1 Suppl 1):40-8. PubMed ID: 11829281
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy for malignant melanoma.
Stoutenburg JP; Schrope B; Kaufman HL
Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
[TBL] [Abstract][Full Text] [Related]
8. Intermediate- and high-risk melanoma.
Agarwala SS
Curr Treat Options Oncol; 2002 Jun; 3(3):205-17. PubMed ID: 12057066
[TBL] [Abstract][Full Text] [Related]
9. The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer.
Eggermont AM; Keilholz U; Testori A; Cook M; Lienard D; Ruiter DJ
Ann Surg Oncol; 2001 Oct; 8(9 Suppl):38S-40S. PubMed ID: 11599896
[TBL] [Abstract][Full Text] [Related]
10. Update on the systemic treatment of malignant melanoma.
Lawson DH
Semin Oncol; 2004 Apr; 31(2 Suppl 4):33-7. PubMed ID: 15124132
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy for patients with high-risk malignant melanoma.
McClay EF
Semin Oncol; 2002 Aug; 29(4):389-99. PubMed ID: 12170442
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
